前列腺癌根治术后PSMA-PET检出淋巴结复发患者省略瘤床放疗的探讨
本研究回顾性分析了46例前列腺癌根治术后PSMA-PET检出仅淋巴结复发的患者,其中24例接受盆腔淋巴结挽救性放疗(NRT)而未行瘤床放疗(PBRT),22例接受瘤床+淋巴结放疗(PB+NRT)。NRT组4年生化失败无生存率为64%,PB+NRT组为67%;NRT组晚期≥2级泌尿毒性1例(4%),PB+NRT组7例(32%)。作者认为对于经选择的患者,在知情同意下可考虑省略瘤床放疗。
要点
- PSMA-PET检出仅淋巴结复发术后患者,省略瘤床放疗的4年BFFS为64%,接受瘤床放疗者为67%。
- 省略瘤床放疗组晚期≥2级泌尿毒性1例(4%),瘤床放疗组7例(32%)。
- 作者认为经选择患者在知情同意下可考虑省略瘤床放疗,但证据尚早。
核心结论
- 本研究为省略瘤床放疗以避免局部毒性提供了早期可行性证据,该队列中多数患者为远处失败。
- 数据提示对于经选择的男性,在知情同意下可考虑省略瘤床放疗。
研究设计与样本
- 回顾性研究,纳入2015年1月至2021年12月在Royal North Shore Hospital(NSCC)、Gosford Hospital(CCCC)或Genesis Care(GC)接受盆腔淋巴结挽救性放疗(NRT)联合同期雄激素剥夺治疗(ADT)的前列腺癌根治术后PSMA-PET检出仅淋巴结复发的患者。
- 共识别46例患者,其中PB+NRT队列22例,NRT队列24例。
- 记录了基线人口学、手术病理、放疗细节、ADT使用及结局。
主要发现
- 与PBRT+NRT组相比,NRT队列分期更低:pT2=7例(29%)、pT3a=15例(63%)、pT3b=1例(4%) vs pT2=0例、pT3a=10例(45%)、pT3b=12例(55%)(p<0.001)。
- NRT队列R1切除率更低:0% vs 63.6%(n=14)(p<0.001)。
- 放疗后中位随访3.9年,NRT组4年生化失败无生存率(BFFS)为64%,PB+NRT组为67%。
- NRT组10例(41.6%)失败中,1例(4%)仅生化失败,2例(8%)瘤床复发并接受进一步挽救治疗,4例(17%)盆腔外淋巴结失败,3例(13%)远处转移。
- NRT组1例(4%)记录晚期≥2级泌尿毒性,PB+NRT组7例(32%);NRT组无晚期≥2级胃肠毒性,PB+NRT组2例(9%)。
临床怎么用
- 作者认为,对于经选择的患者,在知情同意下可考虑省略瘤床放疗。
局限性
- 本研究为早期证据,结论需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nodal only recurrence post radical prostatectomy (RP) is increasingly recognised in the PSMA scan era. Management is controversial with a curative approach usually incorporating prostate bed and nodal irradiation (PB + NRT) in combination with long-term hormonal therapy. It is unknown whether omitting prostate-bed irradiation (PBRT) is safe in a subgroup of these patients. PURPOSE: To document the outcomes for pelvic nodal only salvage radiation therapy (NRT) plus concurrent androgen deprivation therapy (ADT) for patients with PSMA PET documented nodal relapses. METHODS AND MATERIALS: Eligible patients included PSMA PET documented nodal only relapses post RP who received NRT with or without PBRT at Royal North Shore Hospital (NSCC), Gosford Hospital (CCCC) or Genesis Care (GC) between January 2015 and December 2021. Baseline demographics, surgical pathology, radiation details, ADT use and outcomes were documented. RESULTS: Forty-six patients were identified, 22 in the PB + NRT cohort and 24 in the NRT cohort. Compared to the PBRT + NRT group, the NRT cohort had lower stage disease (pT2 = 7 (29 %), pT3a = 15 (63 %), pT3b = 1 (4 %) vs pT2 = 0, pT3a = 10 (45 %), pT3b = 12 (55 %)) (p=<0.001) and lower rates of R1 resection (0 % vs 63.6 % (n = 14)) (p < 0.001) respectively. The median follow-up from radiotherapy was 3.9 years.Four-year biochemical failure- free survival (BFFS) was 64 % in the NRT group vs 67 % in the PB + NRT group. Of the ten (41.6 %) failures in the NRT group, 1 (4 %) was a biochemical failure only, 2 (8 %) recurred in the PB and received further salvage treatment, 4 (17 %) had nodal failure outside the pelvis and 3 (13 %) had distant metastases.One patient (4 %) in the NRT group recorded late grade ≥2 GU toxicity compared with 7 (32 %) in the PB + NRT. No patients in the NRT group recorded late grade ≥2 GI toxicity compared with 2 (9 %) in the PB + NRT cohort. CONCLUSION: This study provides early evidence for the feasibility of PBRT sparing to avoid local toxicity. Most patients in this cohort failed distantly. This data suggests that for selected men PB-avoidance may be considered given informed consent.
引用
- Challis B, Kneebone A, Eade T, et al. Avoiding prostate bed radiation for the PSMA-PET detected nodal recurrence patient post prostatectomy. Clin Transl Radiat Oncol. 2024. PMID: 39676999. doi:10.1016/j.ctro.2024.100896
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。